Literature DB >> 12769861

Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding.

Xia Lin1, Baohua Sun, Min Liang, Yao-Yun Liang, Andreas Gast, Jeffrey Hildebrand, F Charles Brunicardi, Frauke Melchior, Xin-Hua Feng.   

Abstract

The transcription corepressor CtBP is often recruited to the target promoter via interaction with a conserved PxDLS motif in the interacting repressor. In this study, we demonstrate that CtBP1 was SUMOylated and that its SUMOylation profoundly affected its subcellular localization. SUMOylation occurred at a single Lys residue, Lys428, of CtBP1. CtBP2, a close homolog of CtBP1, lacked the SUMOylation site and was not modified by SUMO-1. Mutation of Lys428 into Arg (K428R) shifted CtBP1 from the nucleus to the cytoplasm, while it had little effect on its interaction with the PxDLS motif. Consistent with a change in localization, the K428R mutation abolished the ability of CtBP1 to repress the E-cadherin promoter activity. Notably, SUMOylation of CtBP1 was inhibited by the PDZ domain of nNOS, correlating with the known inhibitory effect of nNOS on the nuclear accumulation of CtBP1. This study identifies SUMOylation as a regulatory mechanism underlying CtBP1-dependent transcriptional repression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12769861     DOI: 10.1016/s1097-2765(03)00175-8

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  65 in total

1.  SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression.

Authors:  Gergana Dobreva; Julia Dambacher; Rudolf Grosschedl
Journal:  Genes Dev       Date:  2003-12-15       Impact factor: 11.361

2.  CtBP contributes quantitatively to Knirps repression activity in an NAD binding-dependent manner.

Authors:  Montserrat Sutrias-Grau; David N Arnosti
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 3.  Evolutionary functional analysis and molecular regulation of the ZEB transcription factors.

Authors:  Alexander Gheldof; Paco Hulpiau; Frans van Roy; Bram De Craene; Geert Berx
Journal:  Cell Mol Life Sci       Date:  2012-02-21       Impact factor: 9.261

4.  CD2AP regulates SUMOylation of CIN85 in podocytes.

Authors:  Irini Tossidou; Rainer Niedenthal; Malte Klaus; Beina Teng; Kirstin Worthmann; Benjamin L King; Kevin J Peterson; Hermann Haller; Mario Schiffer
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

Review 5.  Cardiac function and disease: emerging role of small ubiquitin-related modifier.

Authors:  Jun Wang
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-12-31

6.  Conserved catalytic and C-terminal regulatory domains of the C-terminal binding protein corepressor fine-tune the transcriptional response in development.

Authors:  Yang W Zhang; David N Arnosti
Journal:  Mol Cell Biol       Date:  2010-11-15       Impact factor: 4.272

7.  Multiple activities contribute to Pc2 E3 function.

Authors:  Michael H Kagey; Tiffany A Melhuish; Shannon E Powers; David Wotton
Journal:  EMBO J       Date:  2004-12-09       Impact factor: 11.598

8.  A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties.

Authors:  Sergey Chupreta; Sam Holmstrom; Lalitha Subramanian; Jorge A Iñiguez-Lluhí
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

9.  SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription.

Authors:  Jens Tiefenbach; Natalia Novac; Miryam Ducasse; Maresa Eck; Frauke Melchior; Thorsten Heinzel
Journal:  Mol Biol Cell       Date:  2006-01-18       Impact factor: 4.138

10.  Role of the C-terminal binding protein PXDLS motif binding cleft in protein interactions and transcriptional repression.

Authors:  Kate G R Quinlan; Alexis Verger; Alister Kwok; Stella H Y Lee; José Perdomo; Marco Nardini; Martino Bolognesi; Merlin Crossley
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.